Slowing the progression of chronic hepatitis B: Early antiviral therapy can help minimize complications

Postgraduate Medicine

Volumn 114, Issue 1, 2003, Pages

  Purow, David B ^a   Jacobson, Ira M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RECOMBINANT ALPHA2B INTERFERON; TENOFOVIR DISOPROXIL; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; BRONCHOSPASM; CHRONIC HEPATITIS; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE TRANSMISSION; DRUG INDICATION; FATIGUE; FEVER; FLU LIKE SYNDROME; HAIR LOSS; HEADACHE; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INJECTION SITE; LIVER FUNCTION; MAJOR CLINICAL STUDY; META ANALYSIS; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; RASH; RETINOPATHY; SEIZURE; SEROCONVERSION; SIDE EFFECT; THROMBOCYTOPENIA; THYROID DISEASE; VIRUS DETECTION; VIRUS HEPATITIS; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 0038487143     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.2003.07.1453     Document Type: Conference Paper

References (26)

1. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001;120(7):1828-53
2. Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993;119(4):312-23
3. Korenman J, Baker B, Waggoner J, et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991;114(8):629-34
4. Lin S-M, Sheen I-S, Chien R-N, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999;29(3):971-5
5. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334(22):1422-7
6. Manesis EK, Hadziyannis SJ. Interferon α treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001;121(1):101-9
7. Lampertico P, Del Ninno E, Manzin A, et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997;26(6):1621-5
8. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341(17):1256-63
9. Lai C-L, Chien R-N, Leung NW. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339(2):61-8
10. Liaw Y-F, Leung NW, Chang T-T, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119(1):172-80
11. Leung NW, Lai C-L, Chang T-T, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33(6):1527-32
12. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124(1):105-17
13. Chang T-T, Liaw Y-F, Guan R, et al. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for four years. (Abstr) Antiviral Ther 2000;5(Suppl 1):44
14. Liaw Y-F, Chien R-N, Yeh C-T, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30(2):567-72
15. Marcellin P, Chang T-T, Lim SG, et al. Adefovir dipivoxil for the treatment of patients with hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348(9):808-16
16. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348(9):800-7
17. Marcellin P, Chang T-T, Lim S-G, et al. Adefovir dipivoxil (ADV) 10 mg for the treatment of patients with HBeAg+ chronic hepatitis B: continued efficacy beyond 48 weeks. (Abstr) Hepatology 2002;36(4 Pt 2):373A
18. Yang H, Westland CE, Delaney WE, et al. Lack of emerging resistance mutations in 467 HBeAg-negative and HBeAg-positive patients with chronic hepatitis B receiving adefovir dipivoxil for 48 weeks. Presented at the 37th annual meeting of the European Association for the Study of the Liver, April 17-21, 2002, Madrid
19. Yang H, Westland CE, Delaney WE, et al. Resistance monitoring in chronic hepatitis B patients exposed to adefovir dipivoxil for 72 to 136 weeks. (Abstr) Hepatology 2001;34:316A
20. Heathcote EJ, Jeffers L, Perrillo R, et al. Sustained antiviral response and lack of viral resistance with long-term adefovir dipivoxil therapy in chronic hepatitis B virus infection. Presented at the 37th annual meeting of the European Association for the Study of the Liver, April 17-21, 2002, Madrid
21. Peters M, Hann HW, Martin P, et al. Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses YMDD mutant hepatitis B virus replication: 48 week preliminary analysis. (Abstr) Hepatology 2002;36(4 Pt 2):374A
22. Benhamou Y, Bochet M, Thibault V, et al. 96 week efficacy and safety of adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in chronic hepatitis B patients co-infected with HIV. Hepatology 2002;36(4):638A
23. Werle B, Wursthorn K, Petersen J, et al. Quantitative analyses of hepatic HBV ccc DNA during the natural history of chronic hepatitis B and adefovir dipivoxil therapy: an international, multicenter study. Hepatology 2002;36(4 Pt 2):296A
24. Lai C-L, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002;123(6):1831-8
25. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46(4):562-8
26. Schiff ER, Dienstag JL, Karayalcin S, et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. Hepatology 2003;38(6):818-26